Protagonist Therapeutics ROA 2015-2022 | PTGX

Current and historical return on assets (ROA) values for Protagonist Therapeutics (PTGX) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Protagonist Therapeutics ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-03-31 $-0.12B $0.35B -33.40%
2021-12-31 $-0.13B $0.35B -35.42%
2021-09-30 $-0.11B $0.37B -30.88%
2021-06-30 $-0.08B $0.40B -26.39%
2021-03-31 $-0.07B $0.30B -26.32%
2020-12-31 $-0.07B $0.32B -29.30%
2020-09-30 $-0.07B $0.22B -35.52%
2020-06-30 $-0.07B $0.23B -43.58%
2020-03-31 $-0.08B $0.14B -55.99%
2019-12-31 $-0.08B $0.16B -52.20%
2019-09-30 $-0.07B $0.16B -50.87%
2019-06-30 $-0.07B $0.15B -46.48%
2019-03-31 $-0.05B $0.13B -33.03%
2018-12-31 $-0.04B $0.14B -27.87%
2018-09-30 $-0.03B $0.15B -19.37%
2018-06-30 $-0.03B $0.14B -17.86%
2018-03-31 $-0.03B $0.15B -25.15%
2017-12-31 $-0.04B $0.16B -34.66%
2017-09-30 $-0.05B $0.11B -50.42%
2017-06-30 $-0.05B $0.07B -53.71%
2017-03-31 $-0.04B $0.08B -51.15%
2016-12-31 $-0.04B $0.09B -66.67%
2016-06-30 $-0.02B $0.03B -352.00%
2016-03-31 $-0.02B $0.00B inf%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.411B $0.027B
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $167.557B 10.19
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.634B 16.78
Biohaven Pharmaceutical Holding (BHVN) United States $10.186B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.637B 0.00
Arcus Biosciences (RCUS) United States $1.751B 44.40
Emergent Biosolutions (EBS) United States $1.570B 6.72
Myovant Sciences (MYOV) United Kingdom $1.212B 0.00
Zymeworks (ZYME) Canada $0.325B 0.00
Gelesis Holdings (GLS) United States $0.111B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.097B 0.00
SQZ Biotechnologies (SQZ) United States $0.091B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00